Research progress of ghrelin on cardiovascular disease

Ming-Jie Yuan, Wei Li and Peng Zhong
Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Hubei Key Laboratory of Cardiology, Jiefang Road 238, Wuchang, 430060 Wuhan, P.R. China
Correspondence: Ming-Jie Yuan (yuanmj@whu.edu.cn)

Ghrelin, a 28-aminoacid peptide, was isolated from the human and rat stomach and identified in 1999 as an endogenous ligand for the growth hormone secretagogue-receptor (GHS-R). In addition to stimulating appetite and regulating energy balance, ghrelin and its receptor GHS-R1a have a direct effect on the cardiovascular system. In recent years, it has been shown that ghrelin exerts cardioprotective effects, including the modulation of sympathetic activity and hypertension, enhancement of the vascular activity and angiogenesis, inhibition of arrhythmias, reduction in heart failure and inhibition of cardiac remodeling after myocardial infarction (MI). The cardiovascular protective effect of ghrelin may be associated with anti-inflammation, anti-apoptosis, inhibited sympathetic nerve activation, regulated autophagy, and endothelial dysfunction. However, the molecular mechanisms underlying the effects of ghrelin on the cardiovascular system have not been fully elucidated, and no specific therapeutic agent has been established. It is important to further explore the pharmacological potential of ghrelin pathway modulation for the treatment of cardiovascular diseases.

Introduction of ghrelin
Ghrelin, a 28-aminoacid peptide, was isolated from the human and rat stomach and identified in 1999 as an endogenous ligand for the growth hormone secretagogue-receptor (GHS-R) [1]. Ghrelin and its functional receptor GHS-R1a and the unspliced, nonfunctional GHSR 1b existed in various human tissues including the heart and vascular [2]. In particular, ghrelin is synthesized and secreted by isolated murine and human cardiomyocytes [3]. In addition to regulating metabolism and appetite, ghrelin exerts widespread physiological effects [4]; recent research has shown a strong relationship between ghrelin and the cardiovascular system [5–7]. Ghrelin has demonstrated cardioprotective effects, including enhancement of the endothelial and vascular function, inhibition of the sympathetic drive, reduction in blood pressure, prevention of atherosclerosis, inhibition of cardiac remodeling after myocardial infarction (MI), and improvement in cardiac function [4,8]. In this review, we will discuss the current evidence and potential mechanisms of ghrelin in cardiovascular disease.

Ghrelin pathway in the heart
The ghrelin/GHS-R1a signaling pathway is complex. In cultured rat aortic smooth muscle cell, small interfering RNA-mediated GHSR knockdown suppressed the activation of Akt and ERK1/2 signaling pathway [9]. In addition, ghrelin protected the cardiomyocytes from ischemia/reperfusion injury and improved the cardiomyocyte survival by suppressing the excessive autophagy through reactive oxygen species (ROS) inhibition [10] and mammalian target of rapamycin (mTOR) induction [11]. Wang et al demonstrated that ghrelin ameliorates impaired angiogenesis of ischemic myocardium through GHS-R1a-mediated AMPK/endothelial nitric oxide synthase (eNOS) signal pathway in diabetic rats [12]. Our team demonstrated that GHSR-1a overexpression significantly enhanced tube formation in human umbilical endothelial cells.
Figure 1. Molecular mechanisms and effect of ghrelin/GHS-R1a on cardiovascular system

**Ghrelin modulates sympathetic activity and hypertension**

Ghrelin actions are mediated by GHS-R1a that is expressed in peripheral tissues and central areas involved in the control of cardiovascular responses to stress. Ghrelin may have central and peripheral effects on sympathetic responses [16]. Tokudome group described the potential mechanisms of ghrelin-mediated regulation of the cardiac autonomic nervous system recently [4,7]. Intracerebroventricular injection of 1 nmol of ghrelin decreases arterial pressure, heart rate, and renal sympathetic nerve activity in conscious rabbits [17]. Ghrelin treatment decreased the cardiac sympathetic nerve activity and reduced the high mortality rate in rats after myocardial infarction [18] as well as in healthy humans [19–21]. In ghrelin knockout MI model, ghrelin treatment decreased plasma epinephrine and norepinephrine levels, indicating that endogenous ghrelin plays a crucial role in sympathetic inhibition [22]. Mager et al. reported that several ghrelin gene variations were associated with blood pressure (BP) levels in subjects with impaired glucose tolerance [23]. In a salt-sensitive rat model, continuous antagonism of GHS-R1a resulted in early elevations in blood pressure and increases in the autonomic nervous activity [24]. Circulating ghrelin concentrations are reported to be inversely correlated with BP [25]. Yu et al. investigated the relationship between ghrelin levels and hypertension and central obesity in 387 female adults; they found that hypertensive individuals exhibited lower levels of circulatory ghrelin, irrespective of the presence of central obesity [26]. The mechanism by which ghrelin regulates BP appears to be related to modulation of the sympathetic nervous system and direct vasodilatory.

**The effect of ghrelin on vascular activity and angiogenesis**

The early research showed that human umbilical vein endothelial cells (HUVECs) express ghrelin and GHS-R1a mRNAs, and ghrelin inhibited fibroblast growth factor-2 (FGF-2) induced proliferation of HUVECs [27]. Hypoxia increased myocardial angiogenesis and cardiac VEGF level, and ghrelin inhibited these hypoxia-induced changes [28]. This is in conflict with another research, according to which, ghrelin stimulates HUVECs proliferation, migration, and angiogenesis through activation of ERK2 and PI3K/Akt signaling [29,30]. We also reported that ghrelin and GHS-R1a overexpression could induce angiogenesis in rats after MI; this process may be associated with the enhancement of VEGF and an anti-apoptosis effect. Furthermore, GHSR-1a overexpression significantly enhanced tube formation in HUVECs under ischemia condition [13,31] and was regulated by the GHSR-1a mediated AMPK/eNOS signal pathway [12]. However, systemic administration of ghrelin did not alter coronary angiogenesis in diet-induced obese mice [32]. Whether ghrelin is an anti-angiogenic factor or a pro-angiogenic factor is still controversial. We
speculate that ghrelin plays a specific role in different cellular condition. In GHSR-1a gene knockout mice, the AMPK activity is notably down-regulated in endothelial cells (ECs) [33]. In human patients metabolic syndrome, ghrelin reverses endothelial dysfunction by increasing nitric oxide bioactivity [34], as well as in isolated small arteries taken from essential hypertensive patients [35]. In pulmonary hypertension, ghrelin levels have been found to be inversely associated with pulmonary arterial pressure [36]. Both in animal and human research, ghrelin could attenuate pulmonary vascular remodeling and decrease pulmonary artery pressure [37–39], partly mediated by the regulation of phosphorylation of glycogen synthase kinase 3 beta (p-GSK3 beta), and preventing endothelial cell damage and maintaining NO release [40].

**Ghrelin and arrhythmia**

Intravenous injection of ghrelin elicited dose-related decrease in heart failure without a significant change in renal sympathetic nerve activity, which suggest that ghrelin has effect on the central nervous system [17]. We and others found that ghrelin significantly decreases the inducibility of ventricular tachyarrhythmias in rats after MI, accompanied by increased connexin43 [41–43]. Furthermore, ghrelin knockout mice showed more malignant arrhythmia and excessive sympathetic active after MI [44], indicating the endogenous ghrelin plays a crucial role in the regulation of electrical activity. The serum ghrelin level in the patients with atrial fibrillation was lower than in the patients with sinus arrhythmia [45].

**The relation between ghrelin and coronary artery disease**

Coronary heart disease is associated with atherosclerosis and inflammatory response. In recent years, ghrelin provides an attractive target for studies of atherosclerosis [46]. Ghrelin inhibits proinflammatory cytokine production in human endothelial cells [47,48], improves endothelial function [34], inhibits vascular smooth muscle cell proliferation [49], and ameliorates atherosclerosis by inhibiting endoplasmic reticulum stress [50]. GHS-R1a knockout mice showed decreased vessel intima-to-media ratio, as well as the smooth muscle cell involving Akt and ERK1/2 signaling [9]. Genetic variants of the ghrelin system are associated with susceptibility to MI and coronary artery disease by investigating seven single-nucleotide polymorphisms (SNPs) covering the GHSR region as well as eight SNPs across the ghrelin gene region in MI patients [51,52]. Increased pericardial active ghrelin content were found in ischemic heart disease patients, suggesting an increased ghrelin production of the chronically ischemic myocardium [53]. Furthermore, Serum ghrelin and VEGF-A levels were significantly higher in the good collateral group with severe coronary artery disease than that in the poor collateral group [54]. In isolated human internal mammary arteries (IMA), ghrelin caused a dose-dependent vasodilation of IMA rings [55] In contrast, plasma ghrelin levels seem to be unaffected in the pathogenesis of coronary slow flow [56]. These findings suggest that ghrelin may be an innovative therapeutic candidate for the prevention and treatment of atherosclerosis and coronary artery disease.

**Ghrelin improved heart failure and inhibited cardiac remodeling after MI**

Both animal and clinical researches have showed that ghrelin improved left ventricular (LV) dysfunction and attenuated the development of LV remodeling [57–59]. We and others have previously reported that ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect and inhibiting myocardial apoptosis [60,61]; we reviewed that GHS-R1a signaling pathway was involved in cardiac remodeling after myocardial infarction [14]. In addition, ghrelin enhanced survival and differentiation of human embryonic stem cell (hESC) in the infarcted heart [62]. Chronic heart failure hearts exhibit impaired ghrelin production and compensatory increase in GHS-R1a expression [63] as well as in acute myocardial infarction [64]; exercise training tended to increase ghrelin levels in heart failure patients [65]. However, GHS-R1a was decreased in diabetic cardiomyopathy and was positively correlated with sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) [66]. In particular, ghrelin could suppress cardiac fibrosis [67]; GHS-R1a deficiency increased Wnt/beta-catenin pathway activation in isoproterenol-induced myocardial fibrosis and induced inflammatory activation with the release of IL-18 [68], the cardioprotective effect of ghrelin against cardiac remodeling may through activating of JAK2/STAT3 signaling and inhibition of STAT1 signaling [69]. Furthermore, ghrelin attenuated cardiac hypertrophy in ghrelin knockout mice by activating the cholinergic anti-inflammatory pathway [70]. Chen recently reported that ghrelin inhibited endothelial-to-mesenchymal transition in a GHS-R1 a/AMPK/Smad7 dependent manner in a rat MI model [71], and ghrelin protects the skeletal muscle and the heart from ischemic damage by sustained autophagy and removes
dysfunctional mitochondria [72]. Ghrelin regulates autophagy via a potentially novel mechanism involved in myocardial infarction [15]. The common variants in the GHS-R1a region are associated with parameters of left ventricular hypertrophy [73], a major risk factor for heart failure and sudden death.

Conclusion

In addition to stimulating appetite and regulating energy balance, ghrelin and its receptor GHS-R1a exert direct effects on the cardiovascular system, such as anti-inflammation, anti-apoptosis, inhibition of sympathetic nerve activation, regulation of autophagy, and endothelial dysfunction [4,6]. However, the molecular mechanisms underlying the effects of ghrelin on the cardiovascular system have not been fully elucidated (Figure 1), and there is no specific therapeutic agent. It is important to explore the pharmacological potential of ghrelin pathway modulation for the treatment of cardiovascular diseases.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Abbreviations

GHS-R, growth hormone secretagogue-receptor; hESC, human embryonic stem cell; MI, myocardial infarction; mTOR, mammalian target of rapamycin; ROS, reactive oxygen species.

References

1. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H. and Kangawa, K. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656–660, https://doi.org/10.1038/45230
2. Gnanapavan, S., Kola, B., Bustin, S.A., Morris, D.G., McGee, P., Fairclough, P. et al. (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 87, 2988–2991, https://doi.org/10.1210/jcem.87.6.8739
3. Iglesias, M.J., Pinedo, R., Blanco, M., Gallego, R., Dieguez, C., Guallar, O. et al. (2004) Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc. Res. 62, 481–488, https://doi.org/10.1016/j.cardiores.2004.01.024
4. Tokudome, T. and Kangawa, K. (2019) Physiological significance of ghrelin in the cardiovascular system. Proc. Jpn Acad. Series B-Physical and Biological Sci. 95, 459–467, https://doi.org/10.2183/pjab.95.032
5. Khatib, M.N., Shankar, A., Kirubakaran, R., Agha, K., Simkhada, P., Gaidhani, S. et al. (2015) Effect of Ghrelin on Mortality and Cardiovascular Outcomes in Experimental Rat and Mice Models of Heart Failure: A Systematic Review and Meta-Analysis. PLoS ONE 10, https://doi.org/10.1371/journal.pone.0126897
6. Gruzdeva, O.V., Borodkina, D.A., Belik, E.V., Akbasheva, O.E., Palicheva, E.I. and Barbarash, O.L. (2019) Ghrelin physiology and pathophysiology: focus on the cardiovascular system. Kardiologya 60, 60–77, https://doi.org/10.18087/kardio.2019.3.10220
7. Tokudome, T., Otani, K., Miyazato, M. and Kangawa, K. (2019) Ghrelin and the heart. Peptides 111, 42–46, https://doi.org/10.1016/j.peptides.2018.05.006
8. Lilleness, B.M. and Frishman, W.H. (2016) Ghrelin and the Cardiovascular System. Cardiol. Rev. 24, 288–297, https://doi.org/10.1097/CRD.0000000000000113
9. Li, J., Zhang, M., Wang, M., Wang, Z., Liu, Y., Zhang, W. et al. (2016) GHSR deficiency suppresses neointimal formation in injured mouse arteries. Biochem. Biophys. Res. Commun. 479, 125–131, https://doi.org/10.1016/j.bbrc.2016.06.029
10. Xu, H., Li, Y., Liu, R., Wu, L., Zhang, C., Ding, N. et al. (2019) Protective effects of ghrelin on brain mitochondria after cardiac arrest and resuscitation. Neuropeptides 76, https://doi.org/10.1016/j.npep.2019.05.007
11. Wang, L., Lu, Y., Liu, X. and Wang, X. (2017) Ghrelin protected neonatal rat cardiomyocyte against hypoxia/reoxygenation injury by inhibiting apoptosis through Akt-mTOR signal. Mol. Biol. Rep. 44, 219–226, https://doi.org/10.1007/s11033-017-0498-2
12. Wang, L., Chen, Q., Li, G. and Ke, D. (2015) Ghrelin ameliorates impaired angiogenesis of ischemic myocardium through GHSR1a-mediated AMPK/eNOS signal pathway in diabetic rats. Peptides 73, 77–87, https://doi.org/10.1016/j.peptides.2015.09.004
13. Yuan, M.-J., Wang, T., Kong, B., Wang, X., Huang, C.-X. and Wang, D. (2016) GHSR-1a is a novel pro-angiogenic and anti-remodeling target in rats after myocardial infarction. Eur. J. Pharmacol. 788, 218–225, https://doi.org/10.1016/j.ejphar.2016.06.032
14. Yuan, M.-J., Huang, H. and Huang, C.-X. (2014) Potential new role of the GHSR-1a-mediated signaling pathway in cardiac remodeling after myocardial infarction. Oncol. Lett. 8, 969–971, https://doi.org/10.3892/ol.2014.2245
15. Yuan, M.-J. and Wang, T. (2020) The new mechanism of Ghrelin/GHSR-1a on autophagy regulation. Peptides 126, https://doi.org/10.1016/j.peptides.2020.102624
16. Shirai, M., Joe, N., Tsuchimochi, H., Sonobe, T. and Schwenke, D.O. (2015) Ghrelin Supresses Sympathetic Hyperexcitability in Acute Heart Failure in Male Rats: Assessing Centrally and Peripherally Mediated Pathways. Endocrinology 156, 3309–3316, https://doi.org/10.1210/EN12015-1333
17. Matsumoto, K., Tsuchihashi, T., Fujii, K., Abe, I. and Lida, M. (2002) Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 40, 694–699, https://doi.org/10.1161/01.HYP.0000035395.51441.10
18. Schwenke, D.O., Tokudome, T., Kishimoto, I., Horio, T., Shirai, M., Cragg, P.A. et al. (2008) Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology 149, 5172–5176, https://doi.org/10.1210/en.2008-0472
19 Lambert, E., Lambert, G., Ika-Sari, C., Dawood, T., Lee, K., Chopra, R. et al. (2011) Ghrelin Modulates Sympathetic Nervous System Activity and Stress Response in Lean and Overweight Men. *Hypertension* **58**, 43–50, https://doi.org/10.1161/HYPERTENSIONAHA.111.171025

20 Soeki, T., Koshiba, K., Niki, T., Kusunose, K., Yamaguchi, K., Yamada, H. et al. (2014) Effect of ghrelin on autonomic activity in healthy volunteers. *Peptides* **62**, 1–5, https://doi.org/10.1016/j.peptides.2014.09.015

21 Zhang, C.J., Bidingmaier, M., Altaye, M., Page, L.C., D’Alessio, D., Tschoep, M.H. et al. (2017) Acute administration of acyl, but not desacyl ghrelin, decreases blood pressure in healthy humans. *Eur. J. Endocrinol.* **176**, 123–132, https://doi.org/10.1530/EJE-16-0789

22 Mao, Y., Tokudome, T., Otani, K., Kishimoto, I., Miyazato, M. and Kangawa, K. (2013) Excessive Sympathoactivation and Deteriorated Heart Function After Myocardial Infarction in Male Ghrelin Knockout Mice. *Endocrinology* **154**, 1854–1863, https://doi.org/10.1210/en.2012-2132

23 Mager, U., Kolehmainen, M., Lindstrom, J., Eriksson, J.G., Valle, T.T., Hamalainen, H. et al. (2006) Association between ghrelin gene variations and blood pressure in subjects with impaired glucose tolerance. *Am. J. Hypertens.* **19**, 920–926, https://doi.org/10.1016/j.amjhyp.2006.02.017

24 Sato, T., Nakashima, Y., Nakamura, Y., Ida, T. and Kojima, M. (2011) Continuous Antagonism of the Ghrelin Receptor Results in Early Induction of Salt-Sensitive Hypertension. *J. Mol. Neurosci.* **43**, 193–199, https://doi.org/10.1007/s12031-010-9414-1

25 Mao, Y., Tokudome, T. and Kishimoto, I. (2016) Ghrelin and Blood Pressure Regulation. *Curr. Hypertens. Rep.* **18**, https://doi.org/10.1007/s11906-015-0622-5

26 Yu, A.P., Ugwu, F.N., Tam, B.T., Lee, P.N., Lai, C.W., Wong, C.S.C. et al. (2018) Ghrelin Axis Reveals the Interacting Influence of Central Obesity and Hypertension. *Front. Endocrinol.* **9**, https://doi.org/10.3389/fendo.2018.00534

27 Conconi, M.T., Nico, B., Guidolin, D., Baiguera, S., Spinazzi, R., Rebuffat, P. et al. (2004) Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo. *Peptides* **25**, 2179–2185, https://doi.org/10.1016/j.peptides.2004.08.011

28 Bavi, F.M., Karimi-Sales, E., Alihemmati, A. and Alipour, M.R. (2019) Effect of ghrelin on hypoxia-related cardiac angiogenesis: involvement of miR-210 signalling pathway. *Arch. Physiol. Biochem.* **9**, 1–6

29 Li, A., Cheng, G., Zhu, G.H. and Tamawski, A.S. (2007) Ghrelin stimulates angiogenesis in human microvascular endothelial cells: Implications beyond GH release. *Biochem. Biophys. Res. Commun.* **353**, 238–243, https://doi.org/10.1016/j.bbrc.2006.11.144

30 Wang, L., Chen, Q., Li, G. and Ke, D. (2012) Ghrelin stimulates angiogenesis via GHSR1a-dependent MEK/ERK and PI3K/Akt signal pathways in rat cardiac microvascular endothelial cells. *Peptides* **33**, 92–100, https://doi.org/10.1016/j.peptides.2011.11.001

31 Yuan, M.-J., Huang, H., Tang, Y.-H., Wu, G.-W., Gu, Y.-W., Chen, Y.-J. et al. (2011) Effects of ghrelin on Cx43 regulation and electrical remodeling after myocardial infarction model. *Regul. Pept.* **179**, 39–42, https://doi.org/10.1016/j.regpep.2012.08.013

32 Khazaie, M. and Taherzandi, Z. (2017) Ghrelin did not change coronary angiogenesis in diet-induced obese mice. *Cell. Mol. Biol.* **63**, 96–99, https://doi.org/10.14715/cmb/2017.63.2.15

33 Zhang, M., Fang, W.-Y., Xu, X.-K., Yuan, F., Wang, W.-G., Fei, J. et al. (2013) AMPK activity is down-regulated in endothelial cells of GHS-R-/- mice. *Int. J. Clin. and Exp. Pathol.* **6**, 1770–1780

34 Li, X., Xia, J., Li, Y., Yang, J., Lu, Q. and Meng, H. (2005) Ghrelin increases endothelial function in patients with metabolic syndrome. *Circulation* **112**, 2986–2992, https://doi.org/10.1161/CIRCULATIONAHA.105.553883

35 Virdis, A., Duranti, E., Colucci, R., Ippolito, C., Tirotta, E., Lorenzini, G. et al. (2015) Ghrelin restores nitric oxide availability in resistance circulation of hypertensive patients: role of NAD(P)H oxidase. *Eur. Heart J.* **36**, 3023–3030

36 Xu, Y., Zhu, J. et al. (2011) Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3 beta/beta-catenin signaling in neonatal rats. *J. Mol. Endocrinol.* **47**, 33–43, https://doi.org/10.1530/JME-10-0143

37 Li, X., Zhou, D.-X., Pan, W.-Z., Zhang, L. and Ge, J.-B. (2013) Circulating ghrelin was negatively correlated with pulmonary arterial pressure in atrial septal defect patients. *Chin. Med. J.* **126**, 3936–3939

38 Schwener, D.O., Tokudome, T., Shirai, M., Hosoda, H., Horio, T., Kishimoto, I. et al. (2008) Exogenous ghrelin attenuates the progression of chronic hypoxia-induced pulmonary hypertension in conscious rats. *Endocrinology* **149**, 237–244, https://doi.org/10.1210/en.2007-0833

39 Yang, D., Liu, Z., Zhang, H. and Luo, Q. (2013) Ghrelin protects human pulmonary artery endothelial cells against hypoxia-induced injury via PI3K-pathway/Akt. *Peptides* **42**, 112–117, https://doi.org/10.1016/j.peptides.2013.01.012

40 Yuan, M.-J., Huang, H., Tang, Y.-H., Wu, G., Gu, Y.-W., Chen, Y.-J. et al. (2011) Effects of ghrelin on Cx43 regulation and electrical remodeling after myocardial infarction in rats. *Peptides* **32**, 2357–2361, https://doi.org/10.1016/j.peptides.2011.10.004

41 Soeki, T., Niki, T., Bando, S., Hisako, S., Takeuchi, H., Kusunose, K. et al. (2010) Ghrelin Protects Heart Against Ischemia-Induced Arrhythmias by Preserving Connexin43 Protein. *Circulation* **122**, 795–801, Epub 2013 Mar 15, https://doi.org/10.1161/CIR.0b013e3181e0333-2

42 Soeki, T., Niki, T., Uematsu, E., Bando, S., Matsuura, T., Kusunose, K. et al. (2013) Ghrelin protects the heart against ischemia-induced arrhythmias by preserving connexin-43 protein. *Heart Vessels* **28**, 795–801, https://doi.org/10.1007/s00383-013-0333-2

43 Mao, Y., Tokudome, T., Otani, K., Kishimoto, I., Nakamichi, M., Hosoda, H. et al. (2012) Ghrelin Prevents Incidence of Malignant Arrhythmia after Acute Myocardial Infarction through Vagal Afferent Nerves. *Endocrinology* **153**, 3426–3434, https://doi.org/10.1210/en.2012-1065

44 Ma, T., Su, Y., Lu, S., Chen, M., Zhong, J., Zhou, Z. et al. (2017) Ghrelin expression and significance in 92 patients with atrial fibrillation. *Anatolian J. Cardiol.* **18**, 99–102

45 Ugwu, F.N., Tam, B.T., Lee, P.N., Lai, C.W., Wang, L.X., Gunnlaugsson, S., Stoll, L.L. et al. (2004) Ghrelin inhibits proinflammatory responses and nuclear factor-kappa B activation in human endothelial cells. *Circulation* **109**, 2221–2226, https://doi.org/10.1161/01.CIR.0000127956.43874.F2

46 Zhang, R. (2017) Ghrelin suppresses inflammation in HUVECs by inhibiting ubiquitin-mediated uncoupling protein 2 degradation. *Int. J. Mol. Med.* **39**, 1421–1427, https://doi.org/10.3892/ijmm.2017.2977
6

50 Xu, S., Ye, F., Li, L., Yan, J., Bao, Z., Sun, Z. et al. (2017) Ghrelin attenuates vascular calcification in diabetic patients with amputation. *Biomed. Pharmacother.* **91**, 1053–1064, https://doi.org/10.1016/j.biopharm.2017.05.031

51 Baessler, A., Fischer, M., Mayer, B., Koehler, M., Wiedmann, S., Stark, K. et al. (2007) Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease. *Hum. Mol. Genet.* **16**, 887–899, https://doi.org/10.1093/hmg/ddm033

52 Hedayatizadeh-Ormaz, A., Rafiei, A., Khajavi, R., Alizadeh-Navaei, R., Mokhberi, V. and Moradzadeh, K. (2014) Association Between Ghrelin Gene (Leu2Met) Polymorphism and Ghrelin Serum Level with Coronary Artery Diseases. *DNA Cell Biol.* **33**, 95–101, https://doi.org/10.1089/dna.2013.2218

53 Sax, B., Merkely, B., Turi, K., Nagy, A., Ahres, A., Hartyanszky, I. et al. (2013) Characterization of pericardial and plasma ghrelin levels in patients with ischemic and non-ischemic heart disease. *Regul. Pept.* **186**, 131–136, https://doi.org/10.1016/j.regpept.2013.08.003

54 Akboga, M.K., Tacyo, G., Demirtas, C.Y., Turkozuglu, S., Boyaci, B. and Cengel, A. (2017) As cardioprotective and angiogenic biomarker, can ghrelin level predict coronary collateral development and severity of coronary atherosclerosis? *Turk Kardiyojolii Dernek Magazine-Archieves of the Turkish Soc. Cardiol.* **45**, 316–323

55 Pearson, J.T., Collie, N., Lambert, R.R., Inagaki, T., Yoshimoto, M., Umetani, K. et al. (2018) Ghrelin Preserves Ischemia-Induced Vasodilation of Male Rat Coronary Vessels Following beta-Adrenergic Receptor Blockade. *Endocrinology* **159**, 1763–1773, https://doi.org/10.1210/endo.2017-03070

56 Celik, O., Demirci, E., Aydin, M., Karabag, T. and Kalci, M. (2017) Evaluation of ghrelin levels and endothelial functions in patients with coronary slow flow phenomenon. *Intervent. Med. Applied Sci.* **9**, 154–159, https://doi.org/10.15666/1566.9.2017.27

57 Nagaya, N., Uematsu, M., Kojima, M., Ikeda, Y., Yoshihara, F., Shimizu, W. et al. (2001) Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. *Circulation* **104**, 1430–1435, https://doi.org/10.1161/hc3601.059575

58 Nagaya, N., Moriya, Y., Yasumura, Y., Uematsu, M., Ono, F., Shimizu, W. et al. (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. *Circulation* **110**, 3674–3679, https://doi.org/10.1161/01.CIR.0000149746.62908.BB

59 Du, C.-K., Zhan, D.-Y., Morimoto, S., Akiyama, T., Morita, K., Akiyama, T., Schwenke, D.O., Hosoda, H. et al. (2014) Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy. *Pharmacol. Res. Perspect.* **2**, e00064–e00064, https://doi.org/10.1002/prp2.64

60 Huang, C.-X., Yuan, M.-J., Huang, H., Wu, G., Liu, Y., Yu, S.-B. et al. (2009) Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammatory effect. *Peptides* **30**, 2286–2291, https://doi.org/10.1016/j.peptides.2009.09.004

61 Raghay, K., Akki, R., Bensaid, D. and Errami, M. (2020) Ghrelin as an anti-inflammatory and protective agent in ischemia/reperfusion injury. *Peptides* **124**, https://doi.org/10.1016/j.peptides.2019.170226

62 Gao, M., Yang, J., Liu, G., Wei, R., Zhang, L., Wang, H. et al. (2012) Ghrelin promotes the differentiation of human embryonic stem cells in infarcted cardiac microenvironment. *Peptides* **34**, 373–379, https://doi.org/10.1016/j.peptides.2012.02.006

63 Beiras-Fernandez, A., Kroeth, S., Weis, F., Lederose, C., Poettinger, T., Dieguez, C. et al. (2010) Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. *Cardiovasc. Res.* **87**, 2222–2228, https://doi.org/10.1093/cvr/cvp184.316

64 Matsumoto, M., Yasuda, S., Miyazaki, S., Kataoka, Y., Hosoda, H., Nagaya, N. et al. (2013) Decreased Serum Ghrelin Levels in Patients with Acute Myocardial Infarction. *Tohoku J. Exp. Med.* **231**, 235–242, https://doi.org/10.1620/tjem.231.235

65 Trippel, T.D., Holzendorf, V., Halle, M., Gelbrich, G., Nolle, K., Duvignat, A. et al. (2017) Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study. *Eisc Heart Fail.* **4**, 56–65, https://doi.org/10.1002/ejhf.12109

66 Sullivan, R., McGirr, R., Hu, S., Tan, A., Wu, D., Charron, C. et al. (2018) Changes in the Cardiac GHSR1a-Ghrelin System Correlate With Myocardial Dysfunction in Diabetic Cardiomyopathy in Mice. *J. Endocrine Soc.* **2**, 178–189, https://doi.org/10.1210/js.2017-00433

67 Yang, C., Liu, J., Liu, K., Du, B., Shi, K., Ding, M. et al. (2018) Ghrelin suppresses cardiac fibrosis of post-myocardial infarction heart failure rats by adjusting the activin A–follistatin imbalance. *Peptides* **99**, 27–35, https://doi.org/10.1016/j.peptides.2017.10.018

68 Wang, M., Qian, L., Li, J., Ming, H., Fang, L., Li, Y. et al. (2019) GHSR Deficiency Exacerbates Cardiac Fibrosis: Role in Macrophage Inflammation Activation and Myofibroblast Differentiation. *Cardiovasc. Res.* **116**, 2091–2102

69 Eid, R.A., Alkhateeb, M.A., Eleawa, S., Al-Hashem, F.H., Al-Shraim, M., El-kott, A.F. et al. (2018) Cardioprotective effect of ghrelin against myocardial infarction-induced left ventricular injury via inhibition of SOD3 and activation of JAK2/STAT3 signaling. *Basic Res. Cardiol.* **113**, https://doi.org/10.1007/s00395-018-0671-4

70 Mao, Y., Tokudome, T., Kishimoto, I., Otani, K., Nishimura, H., Yamaguchi, O. et al. (2015) Endogenous Ghrelin Attenuates Pressure Overload-Induced Cardiac Hypertrophy via a Cholinergic Anti-Inflammatory Pathway. *Hypertension* **65**, 1238–1244, https://doi.org/10.1161/HYPERTENSIONAHA.114.04864

71 Chen, H., Liu, Y., Gai, Q., Zhu, X., Zeng, L., Meng, J. et al. (2019) Ghrelin attenuates myocardial fibrosis after acute myocardial infarction via inhibiting endothelial-to mesenchymal transition in rat model. *Peptides* **111**, 118–126, https://doi.org/10.1016/j.peptides.2018.09.001

72 Ruizi, G., Bortolotti, F., Falcione, A., Dal Ferro, M., Ukwich, L., Macedo, A. et al. (2015) AAV-mediated in vivo functional selection of tissue-protective factors against ischaemia. *Nat. Commun.* **6**, 7388, https://doi.org/10.1038/ncomms8388

73 Baessler, A., Kwtke, A.E., Fischer, M., Koehler, M., Reinha, W., Erdmann, J. et al. (2006) Association of the ghrelin receptor gene region with left ventricular hypertrophy in the general population - Results of the MONICA/KORA Augsburg Echocardiographic Substudy. *Hypertension* **47**, 920–927, https://doi.org/10.1161/01.HYP.0000215180.32274.c8